<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103842</url>
  </required_header>
  <id_info>
    <org_study_id>14-000639</org_study_id>
    <nct_id>NCT02103842</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids to Combat Sarcopenia</brief_title>
  <official_title>Omega-3 Fatty Acids to Combat Sarcopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how omega-3 fatty acids influence muscle protein
      metabolism and mitochondrial physiology in the context of human aging.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Muscle protein synthesis</measure>
    <time_frame>Baseline and following 4 months intervention</time_frame>
    <description>Skeletal muscle protein synthesis will be measured from the rate of incorporation of infused amino acids measured by mass spectrometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Muscle mitochondrial function</measure>
    <time_frame>Baseline and following 4 months intervention</time_frame>
    <description>Mitochondrial function will be measured in isolated mitochondria by high-resolution respirometry.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Omega-3 fatty acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take 3.9g/day of Eicosapentaenoic acid and docosahexaenoic acid for 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acids</intervention_name>
    <arm_group_label>Omega-3 fatty acids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-35 or 65-85 years

        Exclusion Criteria:

          1. Current use of omega-3 nutritional supplements

          2. Fasting plasma glucose â‰¥126 mg/dL

          3. Active coronary artery disease

          4. Participation in structured exercise (&gt;3 times per week for 30 minutes or longer)

          5. Smoking

          6. Medications known to affect muscle metabolism (e.g., beta blockers, corticosteroids,
             tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, anticoagulants)

          7. Renal failure (serum creatinine &gt; 1.5mg/dl)

          8. Chronic active liver disease (Bilirubin &gt; 17mmol/L, AST&gt;144IU/L, or ALT&gt;165IU/L)

          9. Anti-coagulant therapy (warfarin/heparin)

         10. INR &gt;3

         11. Use of systemic glucocorticoids

         12. Chronic use of NSAIDS or aspirin

         13. Pregnancy or breastfeeding

         14. Alcohol consumption greater than 2 glasses/day

         15. Hypothyroidism

         16. Fish or shellfish allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian R Lanza, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ian R. Lanza</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

